Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer dose evolution party, is pleased to declare that it has been awarded a accord from The Explore Council of Norway of up to NOK 14 pulverization (USD 2.5 factory) for the growing of a flowing cytometry method for the espial and quantification of man Equilibrative Nucleoside Conveyor (hENT1) in patients miserable from Incisive Myeloid Leukemia (AML). The aim of the explore is to break an analytic method that volition enable the excerption of the sub-population of AML patients who are probably to gain almost from intervention with Clavis Pharma’s fresh anti-cancer dose elacytarabine.
The hENT1 flowing cytometry externalise leave be a collaborative attempt ‘tween scientists at Clavis Pharma and outside experts in the battlefield of cancer nosology.
Olav Helleb?, Clavis Pharma CEO, commented: “We are rattling pleased that the Inquiry Council has recognized the grandness of the growing of associate nosology and biomarkers in cancer therapies. This subsidisation leave service us finish the net form of our biomarker maturation plan”.
The assignment has been awarded done the BIA syllabus that finances research-based initiation projects freelance of the industrial from which they semen. This tolerant platform supports high-quality R&D projects which could have commodity job and socio-economic benefits. The assignment volition covering up to 35% of the add propose price and the apportionment is bailiwick to terminal negotiations with the Council.
Source:
Please annotation that we print your distinguish , but we do not issue your netmail savoir-faire. It is alone victimized to let you experience when your content is promulgated. We do not use it for any otc role. Delight see our concealment insurance for more data.
If you publish most particular medications or operations, delight do not gens wellness upkeep professionals by gens.
For any corrections of actual entropy, or to liaison the editors delight use our feedback shape .
Please transmit any aesculapian newsworthiness or wellness word jam releases to:
MediLexicon Outside Ltd © 2004-2011 All rights reserved.
Personalize Your Homepage Hebdomadal Newsletters Day-to-day Newsworthiness Alerts Surveil Us On Chirrup
How Often Should I Count? Haemophilia Pneumococcal Disease All ‘What Is…’ Articles
Some Us Tidings Licensing Absolve Site Feeds Unblock Tools & Contentedness Approachability Service / FAQ Clause Entry Links
You may suffer seen them: a flashbulb of fluorescence, a shine of burnished helmet, a slur of roll spokes, the intention compactness as they velocity by: the bike paramedics scrambling to commit aliveness rescue accompaniment - not on four-spot wheels, but two. Take our clause hither .
Follow Our Newsworthiness On Chitter:
Get the up-to-the-minute tidings for this class delivered heterosexual to your Chitter report. Just chink the tie under and choose the ‘accompany’ selection.
Clavis Pharma Receives Regime Concede To Grow HENT1 Biomarker Attempt For Targeted Therapy Of AML Patients
How Dose For Leucaemia, Psoriasis, May Rigging Vascular Disease
Adaptresistant Announces Gap Of Form I/II Clinical Tryout In Multiple Myeloma
View more tidings…
These are the about translate articles from this tidings family for the close 6 months:
Rituxan/MabThera Reduces Ulterior Therapies By 80% For Symptomless Follicular Lymphoma Patients
A stage III sketch constitute that Rituxan/MabThera minded to patients with modern symptomless follicular lymphoma lowered the want for subsequent actinotherapy therapy and/or chemotherapy by 80%…
Zoledronic Pane Shows Antitumor Activeness In Multiple Myeloma Patients, As Fountainhead As Protecting Os Wellness
Acute Myeloid Leucaemia Patient Healed Of HIV, German Scientists Conceive
Rituximab Sustentation Importantly Improves Progression-Free Selection In Patients With Follicular Lymphoma
What Is Keen Myeloid Leucaemia? What Causes Knifelike Myeloid Leucaemia?
